Harbour BioMed Added to Stock Connect, Expanding China Market Access
Harbour BioMed's shares have been officially included in the Stock Connect eligible securities list, allowing qualified mainland China investors to trade the company's stock.
Harbour BioMed (HKEX: 02142.HK) has officially been added to the eligible securities list for the Stock Connect program, effective immediately. This inclusion grants qualified investors in mainland China the ability to trade the company's shares on the Hong Kong Stock Exchange.
The inclusion marks a significant step for Harbour BioMed, a biopharmaceutical company focused on developing novel therapies for cancer and immunological diseases. The move is expected to enhance the company's visibility and accessibility to a broader investor base within China's capital markets.
Stock Connect facilitates cross-border investment by linking the stock exchanges of Hong Kong, Shanghai, and Shenzhen. Harbour BioMed's addition to this program is anticipated to boost the liquidity and investor interest in its shares among mainland Chinese institutions and individuals.
The company continues to advance its drug development pipeline, with several programs targeting significant unmet medical needs in oncology and immunology.